| Literature DB >> 28730335 |
Amana Saadallah-Kallel1, Rania Abdelmaksoud-Dammak1, Mouna Triki1, Slim Charfi2, Abdelmajid Khabir2, Tahia Sallemi-Boudawara2, Raja Mokdad-Gargouri3.
Abstract
Aberrant DNA methylation of CpG islands occurred frequently in CRC and associated with transcriptional silencing of key genes. In this study, the CIMP combined with MLH1 or p16 INK4a methylation status was determined in CRC patients and correlated with clinicopathological parameters and overall survival. Our data showed that CIMP+ CRCs were identified in 32.9% of cases and that CACNAG1 is the most frequently methylated promoter. When we combined the CIMP with the MLH1 or the p16 INK4a methylation status, we found that CIMP-/MLH1-U (37.8%) and CIMP-/p16 INK4a -U (35.4%) tumors were the most frequent among the four subtypes. Statistical analysis showed that tumor location, lymphovascular invasion, TNM stage, and MSI differed among the group of patients. Kaplan-Meier analyses revealed differences in overall survival according to the CIMP combined with MLH1 or p16 INK4a methylation status. In a multivariate analysis, CIMP/MLH1 and CIMP/p16 INK4a methylation statuses were predictive of prognosis, and the OS was longer for patients with tumors CIMP-/MLH1-M, as well as CIMP-/p16 INK4a -M. Furthermore, DNMT1 is significantly overexpressed in tumors than in normal tissues as well as in CIMP+ than CIMP- tumors. Our results suggest that tumor classification based on the CIMP status combined with MLH1 or p16 INK4a methylation is useful to predict prognosis in CRC patients.Entities:
Keywords: Colorectal cancer; CpG island methylator phenotype; MLH1; Prognosis; p16 INK4a
Mesh：
Substances：
Year: 2017 PMID： 28730335 DOI： 10.1007/s12032-017-1007-1
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064